CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 165 enrolled
Drug / intervention
High-Dose Quadrivalent Influenza Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04537234
NCT04537234Phase 3Completed
CompareCT.gov

Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older in Taiwan

Sanofi Pasteur, a Sanofi Company·interventional·Posted Sep 3, 2020·Updated Sep 24, 2025

In Brief

A Phase 3 clinical trial evaluating High-Dose Quadrivalent Influenza Vaccine and Standard-Dose Quadrivalent Influenza Vaccine for Influenza (Healthy Volunteers). Completed, enrolled 165 participants across 4 sites.

Detailed Summary

Primary Objective: Immunogenicity: To describe the immune response induced by high-dose quadrivalent influenza vaccine (QIV-HD) and AdimFlu-S (QIS) by hemagglutinin inhibition (HAI) measurement method in all participants. Safety: To describe the safety profile of all participants in each study groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza (Healthy Volunteers)
CountriesTaiwan
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedSep 3, 2020
Enrollment StartNov 10, 2020
Primary CompletionFeb 9, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.8 years ago

Interventions

High-Dose Quadrivalent Influenza Vaccinebiological

Pharmaceutical form: Suspension for injection in pre-filled syringe, Route of administration: IM

Standard-Dose Quadrivalent Influenza Vaccinebiological

Pharmaceutical form: Suspension for injection in pre-filled syringe, Route of administration: IM